What are the latest clinical trials for Colorectal Cancer in 2026

Latest Clinical Trials for Colorectal Cancer in 2026

I appreciate your question about current clinical trials. Based on the medical guidelines I have access to, I can share what the latest treatment approaches and research directions are for colorectal cancer, though I should note that my specific trial information reflects data through late 2025.

Current Research Directions (2025-2026)

According to NCCN Guidelines Version 5.2025 for Colon Cancer, the field is actively exploring several promising areas:

1. Immunotherapy for Advanced Colorectal Cancer

For patients with specific tumor characteristics, checkpoint inhibitor immunotherapy is a major focus:

• dMMR/MSI-H tumors (deficient mismatch repair/microsatellite instability-high): Checkpoint inhibitors including nivolumab ± ipilimumab, pembrolizumab, dostarlimab, and cemiplimab are being studied and used
• POLE/POLD1 mutations with ultra-hypermutated phenotype (TMB>50 mut/Mb): These patients show enhanced immune responses and are candidates for immunotherapy trials

2. Targeted Therapy Combinations

Recent guideline updates highlight emerging targeted approaches:

• HER2-amplified colorectal cancer: Anti-HER2 therapies combined with signal transduction inhibitors (trastuzumab with pertuzumab, tucatinib, or lapatinib) for patients with RAS and BRAF wild-type tumors
• BRAF V600E mutations: Encorafenib combined with cetuximab or panitumumab plus chemotherapy (FOLFOX)

3. Intensive Chemotherapy Regimens

Studies continue evaluating:

• FOLFIRINOX (combination of 5-FU, leucovorin, irinotecan, and oxaliplatin) ± bevacizumab for metastatic disease
• FOLFOXIRI (FOLFOX + irinotecan) plus bevacizumab, particularly for patients with initially unresectable liver metastases

4. Early Detection and Monitoring

Several FDA-approved blood and stool-based tests are now available or in late-stage trials:

• Shield (Guardant Health): FDA-approved blood test for primary colorectal cancer screening (approved July 2024)
• Cologuard Plus (Exact Sciences): FDA-approved stool DNA test (approved October 2024)
• ColoSense (Geneoscopy): FDA-approved stool RNA test (approved May 2024)
• Freenome CRC Blood Test: PMA application submitted; uses AI/machine learning analyzing genomic and epigenomic biomarkers

5. Molecular Residual Disease (MRD) Testing

Research is advancing in detecting remaining cancer cells after treatment:

• Guardant LUNAR/Reveal: Plasma-based ctDNA (circulating tumor DNA) assays that detect MRD without requiring tumor tissue sequencing
• These tests help guide surveillance schedules and adjuvant therapy decisions

How to Find Specific 2026 Trials

To locate active clinical trials for your specific situation, I recommend:

1. ClinicalTrials.gov (www.clinicaltrials.gov) - Search for "colorectal cancer" and filter by:

   • Status: "Recruiting" or "Active, not recruiting"
   • Location: Your state/region
   • Your specific tumor characteristics (if known)

2. NCCN Member Institutions - Many major cancer centers have dedicated trial coordinators

3. Cancer-Specific Resources:

   • American Cancer Society (1-[phone removed])
   • National Cancer Institute (1-800-4-CANCER)
   • Your oncologist's institution

Questions to Ask Your Oncology Team

Since trial eligibility depends heavily on your specific situation, ask your doctor:

1. "Are there any clinical trials available for my specific type of colorectal cancer (stage, location, biomarker status)?"

2. "What are the eligibility requirements, and do I meet them?"

3. "What are the potential benefits and risks compared to standard treatment?"

4. "How will the trial affect my treatment schedule and monitoring?"

5. "What happens to my care if I need to stop the trial?"

---

Important Context

According to the NCCN Guidelines, treatment decisions for colorectal cancer increasingly depend on:

• Tumor location (left-sided vs. right-sided)
• Biomarker status (KRAS, NRAS, BRAF mutations; HER2 amplification; MSI/MMR status; POLE/POLD1 mutations)
• Stage (early, locally advanced, or metastatic)
• Previous treatments received

This means the "best" trial for you will be highly individualized based on these factors.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about clinical trial participation.